Monepantel is a well-known veterinary drug. It has been shown to have an effect on the abnormal accumulation of protein in cells. This accumulation is associated with motor neurone disease. Monepantel works by increasing the recycling and removal of excessive or abnormal proteins.
Phase 1 of this trial was a small study that focused on testing the safety of monepantel tablets in people with motor neurone disease. Early results from phase 1 of this trial suggest that it was well tolerated. In February of 2024, the pharmaceutical running the trial, PharmAust Ltd, announced that the phase 1 trial had moved to an Open-Label Extension program. This means that the 12 patients who took part in the phase 1 trial will continue on the medication and will continue to be monitored.
This trial is not currently recruiting. A larger Phase 2 study of Monepantel is hoped to commence in 2024.
For more information visit clinicaltrials.gov
For additional information on how this therapy works you can read a summary from the ALS Therapy Development Institute (ALS TDI)
